TORONTO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) today announced that its President and CEO, Anthony Giovinazzo, will present a corporate overview at the Rodman & Renshaw 17th Annual Global Investment Conference and the BioCentury 22nd Annual NewsMakers in the Biotech Industry Conference. Details regarding the conferences are as follows:
|Rodman & Renshaw 17th Annual Global Investment Conference|
|Wednesday, September 9, 2015 at 11:15 a.m. EDT|
|St. Regis Hotel, New York, NY|
|BioCentury 22nd Annual NewsMakers in the Biotech Industry Conference|
|Thursday, September 10, 2015 at 1:30 p.m. EDT|
|Millennium Broadway Hotel, New York, NY|
|A live webcast of the presentation will be available at www.cynapsus.ca on the calendar and alerts page.|
Cynapsus is a specialty Central Nervous System pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson's disease (PD). The Company recently completed a Phase 2 clinical trial for its lead product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a "turning ON" medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit a new drug application in 2016.
This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including without limitation, the expected NDA submission of APL-130277 in 2016. These forward-looking statements include information about possible or assumed future results of the Company's business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company's current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption "Risk Factors" in the Company's Form 10-Q filed with the United States Securities and Exchange Commission (the "SEC") on August 14, 2015 and its other filings and reports in the United States with the SEC available on the SEC's web site at www.sec.gov, and in Canada with the various Canadian securities regulators, which are available online at www.sedar.com. Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law.
Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.
CONTACT: Company Contacts: Cynapsus Therapeutics Anthony Giovinazzo President and CEO (416) 703-2449 x225 email@example.com Cynapsus Therapeutics Andrew Williams COO & CFO (416) 703-2449 x253 firstname.lastname@example.org Investor Contact: The Trout Group Marcy Nanus Senior Vice President (646) 378-2927 email@example.com Media Contact: Russo Partners LLC Matt Middleman (212) 845-4272 firstname.lastname@example.orgSource:Cynapsus Therapeutics Inc.